文献速递炎症性肠病

妊娠期母亲抗肿瘤坏死因子治疗后的儿童出生后3年内感染

Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-24

基于丹麦、芬兰和瑞典2006—2013年人群队列,比较抗肿瘤坏死因子(anti-TNF)治疗、非生物制剂系统治疗及一般人群儿童出生后3年内感染风险。抗TNF组和非生物制剂组感染住院风险均升高,但风险不持续至3年,且与孕晚期治疗或联合治疗无关。

要点

  • 抗TNF组第一年感染住院的调整发病率比(IRR)为1.43(95%CI 1.23-1.67)。
  • 非生物制剂系统治疗组第一年感染住院的调整IRR为1.14(95%CI 1.07-1.21)。
  • 抗TNF组第二年抗生素处方略增,IRR为1.19(95%CI 1.11-1.29)。

核心结论

  • 抗TNF和非生物制剂系统治疗均与儿童感染风险增加相关,但风险不持续至出生后3年。
  • 作者认为该发现可能提示真实风险,也可能源于疾病严重度和就医行为等未调整混杂。

研究设计与样本

  • 2006—2013年丹麦、芬兰和瑞典基于人群的队列研究。
  • 抗TNF组1027名儿童,非生物制剂系统治疗组9346名儿童,一般人群对照1617886名儿童,随访3年。

主要发现

  • 第一年感染住院调整IRR:抗TNF组1.43(95%CI 1.23-1.67),非生物制剂组1.14(95%CI 1.07-1.21)。
  • 额外调整不良出生结局后,第一年感染住院调整IRR:抗TNF组1.29(95%CI 1.11-1.50),非生物制剂组1.09(95%CI 1.02-1.15)。
  • 第二年抗生素处方调整IRR:抗TNF组1.19(95%CI 1.11-1.29),非生物制剂组1.10(95%CI 1.07-1.13)。
  • 不同抗TNF药物之间、孕晚期治疗与否、单药与联合非生物制剂系统治疗之间未见差异。

局限性

  • 原文指出发现可能反映真实风险,也可能源于疾病严重度和就医行为等未调整混杂。
  • 原文结论提示该风险可能使风险-获益权衡倾向于即使在孕晚期也继续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most anti-tumour necrosis factor (anti-TNF) agents are transferred across the placenta and may increase paediatric susceptibility to infections. AIMS: To assess the risk of paediatric infections after maternal anti-TNF treatment. METHODS: Population-based cohort study in Denmark, Finland and Sweden 2006-2013 in which 1027 children born to women with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis or inflammatory bowel disease, treated with anti-TNF, and 9346 children to women with non-biologic systemic treatment, were compared to 1 617 886 children of the general population. Children were followed for 3 years. RESULTS: Adjusted by maternal age, parity, smoking, body mass index, country and calendar year, the incidence rate ratios with 95% confidence interval (CI) for hospital admissions for infection in the first year were 1.43 (1.23-1.67) for anti-TNF and 1.14 (1.07-1.21) for non-biologic systemic treatment, and 1.29 (1.11-1.50) and 1.09 (1.02-1.15), respectively, when additionally adjusting for adverse birth outcomes. There was a slight increase in antibiotic prescriptions in the second year for anti-TNF, 1.19 (1.11-1.29), and for non-biologic systemic treatment, 1.10 (1.07-1.13). There was no difference among anti-TNF agents, treatment in the third trimester, or between mono/combination therapy with non-biologic systemic treatment. CONCLUSIONS: Both anti-TNF and non-biologic systemic treatment were associated with an increased risk of paediatric infections. However, reassuringly, the increased risks were present regardless of treatment in the third trimester, or with combination treatment, and were not persistent during the first 3 years of life. Our findings may indicate a true risk, but could also be due to unadjusted confounding by disease severity and healthcare-seeking behaviour. This may in turn shift the risk-benefit equation towards continuation of treatment even in the third trimester.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bröms G, Kieler H, Ekbom A, et al. Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2020. PMID: 32706178. doi:10.1111/apt.15971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。